Anecdotal studies of antitumour necrosis factor agents
Disease | Author(s) | Drugs | Patients (n) |
Adult Still’s disease | Huffstutter et al501 | Infliximab | 2 |
Kraetsch et al502 | Infliximab | 6 | |
Weinblatt et al503 | Etanercept | 12 | |
Fernandez-Nebro504 | Etanercept | 3 | |
Amyloidosis | Elkayam et al505 | Infliximab | 1 |
Gottenberg et al506 | Etanercept/infliximab | 15 | |
Ortiz-Santamaria et al507 | Infliximab | 6 | |
Tomero et al508 | Infliximab | 12 | |
Smith et al509 | Etanercept | 1 | |
Aphthous stomatitis | Robinson and Guitart510 | Etanercept | 1 |
Vujevich and Zirwas511 | Adalimumab | ||
Atzeni et al512 | Etanercept | 1 | |
Back pain (including sciatica) | Sakellariou et al513 | lnfliximab | 1 |
Genevay et al514 | Etanercept | 10 | |
Behçet’s disease | Estrach et al515 | Infliximab/adalimumab | 7 |
Gulli et al516 | Infliximab | 1 | |
Hassard et al517 | Infliximab | 1 | |
Licata et al518 | Infliximab | 1 | |
Magliocco and Gottlieb519 | Etanercept | 20 | |
Morillas-Arques et al520 | Adalimumab/etanercept | ||
Rozenbaum et al521 | Anti-TNF | ||
Saulsbury and Mann522 | Infliximab | ||
Sangle et al523 | Infliximab | 1 | |
Sfikakis et al524 | Infliximab | 5 | |
Sfikakis525 | Infliximab | 11 | |
Ribi et al526 | Infliximab | 1 | |
Sweiss et al527 | Infliximab | 3 | |
van Laar et al528 | Adalimumab | 6 | |
Bronchiolitis | Cortot et al529 | Etanercept | 1 |
Cirrhosis and alcoholic hepatitis | Naveau et al530 | Infliximab | 36 |
Spahr et al531 | Infliximab | 20 | |
Wendling et al282 | Infliximab | 1 | |
Menon et al532 | Etanercept | 13 | |
Congestive heart failure | Anker et al582 | Infliximab/etanercept | 150 |
Cutaneous T-cell lymphoma | Tsimberidou et al533 | Etanercept | 13 |
Dermatitis, hidradenitis, miscellaneous | Bongartz et al339 | Infliximab | |
Cortis et al534 | Etanercept | ||
Cummins et al535 | Etanercept | ||
Zeichner et al536 | Adalimumab | 1 | |
Cusak and Buckley537 | Etanercept | 6 | |
Dermatomyositis | Hengstman et al538 | Infliximab | 2 |
Miller et al539 | Etanercept | 10 | |
Sprott et al540 | Etanercept | 1 | |
Nzeusseu et al541 | Infliximab | 1 | |
Saadeyh542 | Etanercept | 4 | |
Norman et al543 | Etanercept | 2 | |
Erythema nodosum | Ortego-Centeno et al120 | Adalimumab | 1 |
Familial Mediterranean fever | Takada et al122 | Etanercept | 2 |
Ozgocmen et al125 | Etanercept | 1 | |
Felty’s syndrome | Ghavami et al128 | Etanercept | 1 |
Giant cell arteritis | Andonopoulos et al126 | Infliximab | 2 |
Cantini et al127 | Infliximab | 4 | |
Tan et al135 | Etanercept | 1 | |
Ahmed et al133 | Adalimumab | 1 | |
Graft vs host disease (acute) | Wolff et al544 | Etanercept | 21 |
Uberti et al545 | Etanercept | 20 | |
Kennedy et al546 | Etanercept | 20 | |
Chiang et al547 | Etanercept | 8 | |
Pavletic et al548 | Etanercept | 4 | |
Andolina et al549 | Etanercept | 1 | |
Graves ophthalmopathy | Paridaens et al550 | Etanercept | 10 |
Hepatitis C | Cacoub et al551 | Interferon | 27 |
McMinn et al552 | Etanercept | 3 | |
Peterson et al553 | Infliximab/etanercept | 24 | |
Pritchard554 | Etanercept | 1 | |
Ince et al555 | Etanercept | 12 | |
Moreno et al556 | Etanercept | 5 | |
Allen and Wolverton470 | Etanercept | 2 | |
Marotte et al557 | Etanercept | 9 | |
Rokhsar et al558 | Etanercept | 1 | |
Magliocco and Gottlieb519 | Etanercept | 3 | |
HIV | Wallis et al559 | Etanercept | 16 |
Immunodeficiency (common variable) | Smith and Skelton560 | Etanercept | 1 |
Lin et al561 | Etanercept | 1 | |
Cepeda et al562 | Etanercept | 7 | |
Inclusion body myositis | Barohn et al563 | Etanercept | 9 (ineffective) |
Singh et al564 | Etanercept | 1 | |
Juvenile-onset HLA-B27- associated severe and refractory heal enthesitis | Olivieri et al565 | Adalimumab | 1 |
Kawasaki’s disease | Weiss et al566 | Infliximab | 1 |
Burns et al567 | Infliximab | 16 | |
Multicentric histiocytosis | Lovelace et al108 | Etanercept | 1 |
Matejicka et al143 | Etanercept | 1 | |
Kovach et al568 | Etanercept | 1 | |
Myelodysplasia | Birnbaum and Gentile569 | Etanercept | 1 |
Deeg et al570 | Etanercept | 14 | |
Rosenfeld and Bedell571 | Etanercept | 19 (ineffective) | |
Raza et al572 | Etanercept | 26 | |
Maciejewski573 | Etanercept | 16 | |
Osteoarthritis (erosive) | Magnano et al574 | Adalimumab | 12 |
Periodic fever (children) | Athreya et al575 | Etanercept | 3 |
Pigmented villonodular synovitis | Kroot et al576 | TNF | |
Polychondritis | Carter578 | Infliximab | 1 |
Ehresman579 | Etanercept | 5 | |
Polymyositis | Hengstman et al538 | Infliximab | 2 |
Sprott et al540 | Etanercept | 1 | |
Adams et al577 | Adalimumab | 2 | |
Pyoderma gangrenosum | Fonder et al580 | Adalimumab | 1 |
Heffernan et al581 | Adalimumab | 1 | |
SAPHO syndrome | Wagner et al131 | Etanercept | 2 |
Moul and Korman132 | Adalimumab | 1 | |
Sarcoidosis | Khanna et al129 | Etanercept | 1 |
Utz et al130 | Etanercept | 17 | |
Heffernan et al134 | Adalimumab | 1 | |
Callejas-Rubio et al584 | Adalimumab | 1 | |
Thumbfart317 | Infliximab | 1 | |
Sweiss et al583 | Infliximab | 3 | |
Hobbs586 | Etanercept | 1 | |
Soiatica | Korhonen et al118 | Infliximab | 12 |
Korhonen et al119 | Infliximab | 40 | |
Tobinick and Davoodifar124 | Etanercept | 43 | |
Scleroderma | Ellman et al587 | Etanercept | 8 |
Bosello et al588 | Etanercept | ||
Lam et al121 | Infliximab | 18 | |
Silicone granulomas | Pasternack et al123 | Etanercept | 4 |
Sjögren’s syndrome | Zandbelt et al589 | Etanercept | 15 (ineffective) |
Sankar et al212 | Etanercept | 14 (ineffective) | |
Pessler et al590 | Etanercept | 1 | |
Still’s disease (includes adult onset) | Fautrel et al591 | Etanercept | 20 (ineffective) |
Stern et al592 | Etanercept | 1 (worsening) | |
Asherson et al593 | Etanercept | 1 | |
Kumari and Uppal594 | Etanercept | 1 | |
Sweet’s syndrome | Gindi et al595 | Etanercept | 1 |
Yamauchi et al596 | Etanercept | 24 | |
Systemic lupus erythematosus | Aringer et al597 | Infliximab | 6 |
Fautrel et al591 | Etanercept | 1 (SCLE) | |
Lurati et al598 | Etanercept | 1 | |
Norman et al543 | Etanercept | 1 (SCLE) | |
Hernandez-Ibarra et al599 | N/A | – | |
Principi et al600 | Infliximab | 1 | |
Takayasu’s arteritis | Hoffman et al601 | Anti-TNF | 15 |
Della Rossa et al602 | Infliximab | 2 | |
Tato et al603 | Adalimumab | 1 | |
TRAPS | Hull et al604 | Etanercept | >50 |
Lamprecht et al605 | Etanercept | 2 | |
Drewe et al606 | Etanercept | 1 | |
Estrach et al607 | Infliximab/adalimumab | 7 | |
Joseph et al607 | Infliximab | 5 | |
Smith et al608 | Etanercept | 7 | |
Braun et al609 | Etanercept/infliximab | 717 (uveitis in AS) | |
Foster et al610 | Etanercept | 20 (ineffective) | |
Biester et al611 | Adalimumab | 18 | |
Foeldvari et al612 | Anti-TNFα | 47 | |
Vazquez-Cobian et al613 | Adalimumab | 14 | |
Reiff et al614 | Etanercept | 10 | |
Schmeling and Horneff615 | Etanercept | 20 (ineffective) | |
Vasculitis* | Booth et al616 | Infliximab | 32 |
Feinstein and Arroyo617 | Etanercept | 1 | |
van der Bijl et al618 | Infliximab | 11 | |
Saji and Kemmotsu619 | Infliximab | 1 (Kawasaki’s disease) | |
Sangle et al523 | Infliximab | 1 (Churg–Strauss) | |
Arbach et al620 | Etanercept/infliximab | 3 | |
Wegener’s granulomatosis | Gause et al621 | Infliximab | 10 |
Sangle et al523 | Infliximab | 3 |
*See also Behçet’s disease, giant cell arteritis,Takayasu’s arteritis, Wegener’s
granulomatosis.
AS, ankylosing spondylitis; SCLE, subacute cutaneous lupus erythematosus.